Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22878238 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL30893488 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17286000 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL22557323 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL22878232 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17284462 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL25305746 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17281987 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL13661301 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL18921646 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346815-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SMN1; SMN2 3594/4885NPC1 2578/4885RAB9A 2153/4885 |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SMN1; SMN2 3594/4885NPC1 2578/4885RAB9A 2153/4885 |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SMN1; SMN2 3594/4885NPC1 2578/4885RAB9A 2153/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SMN1; SMN2 3594/4885NPC1 2578/4885RAB9A 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.